8-K 1 y91554e8vk.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2003 HALSEY DRUG CO., INC. 695 North Perryville Road, Rockford, Illinois 61107 (815-399-2060) Incorporated under Commission File Number I.R.S. Employer the laws of State of New York 1-10113 Identification Number 11-0853640 Item 5. Other Events On November 6, 2003, Halsey Drug Co., Inc. (the "Company") issued a press release disclosing its intention to restructure the Company's operations to focus its efforts on research and development related to certain proprietary finished dosage product. A copy of the Company's press release is attached as Exhibit 99.1 hereto. Item 7. Financial Statements and Exhibits. (b) Exhibits Exhibit Number Description ------ ----------- 99.1 Press Release of Halsey Drug Co., Inc. dated November 6, 2003. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. HALSEY DRUG CO., INC. By: /s/ Peter A. Clemens ------------------------------------------ Peter A. Clemens Vice President & Chief Financial Officer Date: November 6, 2003 3 EXHIBIT INDEX ------------- Exhibit Number Description ------ ------------ 99.1 Press Release of Halsey Drug Co., Inc. dated November 6, 2003. 4